Compare WT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WT | AUPH |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2011 | 2014 |
| Metric | WT | AUPH |
|---|---|---|
| Price | $18.37 | $15.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $17.33 | $17.25 |
| AVG Volume (30 Days) | ★ 3.3M | 1.1M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | 127.27 | ★ 5075.00 |
| EPS | 0.75 | ★ 2.07 |
| Revenue | ★ $493,753,000.00 | $283,055,000.00 |
| Revenue This Year | $35.04 | $17.54 |
| Revenue Next Year | $8.68 | $15.74 |
| P/E Ratio | $23.27 | ★ $7.76 |
| Revenue Growth | 15.43 | ★ 20.38 |
| 52 Week Low | $8.18 | $7.29 |
| 52 Week High | $17.87 | $16.54 |
| Indicator | WT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 70.09 | 60.86 |
| Support Level | $13.07 | $14.56 |
| Resistance Level | N/A | $16.28 |
| Average True Range (ATR) | 0.74 | 0.47 |
| MACD | 0.37 | 0.04 |
| Stochastic Oscillator | 96.85 | 75.84 |
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.